PRE-CLINICAL DEVELOPMENT OF AN IP3K INHIBITOR FOR SOLID CANCER TREATMENT (Q2035314)

From EU Knowledge Graph
Revision as of 04:31, 20 March 2020 by DG Regio (talk | contribs) (‎Removed claim: co-financing rate (P837): 50.00000049829505 percent)
Jump to navigation Jump to search
Project in Italy financed by DG Regio
Language Label Description Also known as
English
PRE-CLINICAL DEVELOPMENT OF AN IP3K INHIBITOR FOR SOLID CANCER TREATMENT
Project in Italy financed by DG Regio

    Statements

    country
    Italy
    0 references
    EU contribution
    501,710.79 Euro
    0 references
    budget
    1,003,421.57 Euro
    0 references
    start time
    13 December 2016
    0 references
    expected end time
    6 July 2019
    0 references
    beneficiary name (string)
    CNR - CONSIGLIO NAZIONALE DELLE RICERCHE
    0 references
    MENARINI RICERCHE S.P.A.
    0 references
    coordinate location

    41°40'3.11"N, 12°30'17.24"E
    0 references
    summary
    IL PROGETTO SI PROPONE LA CARATTERIZZAZIONE PRECLINICA DEL MEN1611, UN NUOVO INIBITORE DI PI3K CHE HA LA CAPACITà DI INIBIRE IN MODO PREFERENZIALE L?ISOFORMA ALFA, WILD TYPE E MUTATA. VERRANNO STUDIATI I DETERMINANTI MOLECOLARI DELLA SENSIBILITà (Italian)
    0 references

    Identifiers

    Italian Unique Project Code
    F57H18000070007
    0 references
     
    Retrieved from "https://linkedopendata.eu/w/index.php?title=Item:Q2035314&oldid=2483109"